IL93053A - Pharmacological preparations and kits for the treatment of pre-menstrual syndrome - Google Patents

Pharmacological preparations and kits for the treatment of pre-menstrual syndrome

Info

Publication number: IL93053A
Authority: IL; Israel
Prior art keywords: kit; accordance; dosage level; range; melatonin
Prior art date: 1989-01-17

Application number

IL9305390A

Other languages

English (en)

Hebrew (he)

Original Assignee

Amr Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-01-17

Filing date

1990-01-15

Publication date

1994-02-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27154756&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL93053(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-01-15 Application filed by Amr Int filed Critical Amr Int

1994-02-27 Publication of IL93053A publication Critical patent/IL93053A/en

Links

206010036618 Premenstrual syndrome Diseases 0.000 title claims abstract description 68
239000008194 pharmaceutical composition Substances 0.000 title claims description 12
238000011282 treatment Methods 0.000 title description 13
YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims abstract description 64
DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims abstract description 64
229960003987 melatonin Drugs 0.000 claims abstract description 63
208000024891 symptom Diseases 0.000 claims abstract description 42
239000000583 progesterone congener Substances 0.000 claims description 26
230000027758 ovulation cycle Effects 0.000 claims description 21
230000029849 luteinization Effects 0.000 claims description 14
229940053934 norethindrone Drugs 0.000 claims description 10
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 10
230000016087 ovulation Effects 0.000 claims description 10
239000000203 mixture Substances 0.000 claims description 9
239000007943 implant Substances 0.000 claims description 7
230000002175 menstrual effect Effects 0.000 claims description 7
230000011599 ovarian follicle development Effects 0.000 claims description 6
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 5
229960004400 levonorgestrel Drugs 0.000 claims description 5
XAVRSHOUEXATJE-FBQZJRKBSA-N 1-[(8s,9s,10r,13s,14s,17s)-3-cyclopentyloxy-10,13-dimethyl-2,7,8,9,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-17-yl]ethanone Chemical compound C([C@H]1[C@@H]2CC[C@@H]([C@]2(CC[C@@H]1[C@@]1(C)CC2)C)C(=O)C)C=C1C=C2OC1CCCC1 XAVRSHOUEXATJE-FBQZJRKBSA-N 0.000 claims description 3
QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 claims description 3
YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 3
229960001910 lynestrenol Drugs 0.000 claims description 3
LVHOURKCKUYIGK-RGUJTQARSA-N Dimethisterone Chemical compound C1([C@@H](C)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C#CC)(O)[C@@]2(C)CC1 LVHOURKCKUYIGK-RGUJTQARSA-N 0.000 claims description 2
IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims description 2
ICTXHFFSOAJUMG-SLHNCBLASA-N Norethynodrel Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 ICTXHFFSOAJUMG-SLHNCBLASA-N 0.000 claims description 2
229960001616 chlormadinone acetate Drugs 0.000 claims description 2
125000004122 cyclic group Chemical group 0.000 claims description 2
229950006690 dimethisterone Drugs 0.000 claims description 2
ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 claims description 2
238000010253 intravenous injection Methods 0.000 claims description 2
229960002985 medroxyprogesterone acetate Drugs 0.000 claims description 2
PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims description 2
229960004296 megestrol acetate Drugs 0.000 claims description 2
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims description 2
229960001652 norethindrone acetate Drugs 0.000 claims description 2
229960001858 norethynodrel Drugs 0.000 claims description 2
229950000796 quingestrone Drugs 0.000 claims description 2
239000000829 suppository Substances 0.000 claims description 2
238000000034 method Methods 0.000 abstract description 8
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 15
230000002354 daily effect Effects 0.000 description 11
229940079593 drug Drugs 0.000 description 10
239000003814 drug Substances 0.000 description 10
229940088597 hormone Drugs 0.000 description 10
239000005556 hormone Substances 0.000 description 10
239000006187 pill Substances 0.000 description 8
229960003387 progesterone Drugs 0.000 description 7
239000000186 progesterone Substances 0.000 description 7
239000002775 capsule Substances 0.000 description 6
230000002124 endocrine Effects 0.000 description 6
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
230000003325 follicular Effects 0.000 description 5
206010006298 Breast pain Diseases 0.000 description 4
206010022998 Irritability Diseases 0.000 description 4
206010024264 Lethargy Diseases 0.000 description 4
208000006662 Mastodynia Diseases 0.000 description 4
230000000694 effects Effects 0.000 description 4
230000003054 hormonal effect Effects 0.000 description 4
230000009467 reduction Effects 0.000 description 4
230000001850 reproductive effect Effects 0.000 description 4
208000011580 syndromic disease Diseases 0.000 description 4
239000003826 tablet Substances 0.000 description 4
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 3
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 3
206010056465 Food craving Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
206010042458 Suicidal ideation Diseases 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000003433 contraceptive agent Substances 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
229940011871 estrogen Drugs 0.000 description 3
239000000262 estrogen Substances 0.000 description 3
229940028334 follicle stimulating hormone Drugs 0.000 description 3
230000002611 ovarian Effects 0.000 description 3
239000000902 placebo Substances 0.000 description 3
229940068196 placebo Drugs 0.000 description 3
230000028327 secretion Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
208000019901 Anxiety disease Diseases 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
208000020401 Depressive disease Diseases 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
102000003946 Prolactin Human genes 0.000 description 2
108010057464 Prolactin Proteins 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
235000019219 chocolate Nutrition 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000002254 contraceptive effect Effects 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
235000019788 craving Nutrition 0.000 description 2
230000000994 depressogenic effect Effects 0.000 description 2
230000008034 disappearance Effects 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000005906 menstruation Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
229940127234 oral contraceptive Drugs 0.000 description 2
239000003539 oral contraceptive agent Substances 0.000 description 2
239000006186 oral dosage form Substances 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
201000000484 premenstrual tension Diseases 0.000 description 2
229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 2
229940097325 prolactin Drugs 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
230000000392 somatic effect Effects 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000011277 treatment modality Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
230000004584 weight gain Effects 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
DHOKBGHAEUVRMO-WYGKVCCSSA-N (8r,9s,13s,14s)-17-ethynyl-13-methyl-2,3,4,6,7,8,9,11,12,14,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ol Chemical compound C1CCCC2=C1[C@H]1CC[C@](C)(C(CC3)(O)C#C)[C@@H]3[C@@H]1CC2 DHOKBGHAEUVRMO-WYGKVCCSSA-N 0.000 description 1
HAKRSIFCTAKBRD-TYFJVFSVSA-N (8s,9s,10r,13s,14s,17s)-17-acetyl-1-methoxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1C[C@@H]2[C@@]3(C)C(OC)CC(=O)C=C3CC[C@H]2[C@@H]2CC[C@H](C(C)=O)[C@]21C HAKRSIFCTAKBRD-TYFJVFSVSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
208000004998 Abdominal Pain Diseases 0.000 description 1
206010000060 Abdominal distension Diseases 0.000 description 1
206010000097 Abdominal tenderness Diseases 0.000 description 1
206010054196 Affect lability Diseases 0.000 description 1
206010001497 Agitation Diseases 0.000 description 1
PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
206010011469 Crying Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
206010015958 Eye pain Diseases 0.000 description 1
208000004262 Food Hypersensitivity Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
208000001456 Jet Lag Syndrome Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000008930 Low Back Pain Diseases 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
208000037490 Medically Unexplained Symptoms Diseases 0.000 description 1
206010027304 Menopausal symptoms Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010027940 Mood altered Diseases 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
102000007399 Nuclear hormone receptor Human genes 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000012868 Overgrowth Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
208000000450 Pelvic Pain Diseases 0.000 description 1
206010064229 Pelvic discomfort Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010037180 Psychiatric symptoms Diseases 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
206010041243 Social avoidant behaviour Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
206010043268 Tension Diseases 0.000 description 1
206010043431 Thinking abnormal Diseases 0.000 description 1
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
208000012886 Vertigo Diseases 0.000 description 1
208000021017 Weight Gain Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000003470 adrenal cortex hormone Substances 0.000 description 1
230000016571 aggressive behavior Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
229960002478 aldosterone Drugs 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
208000028004 allergic respiratory disease Diseases 0.000 description 1
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
235000020661 alpha-linolenic acid Nutrition 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000006399 behavior Effects 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
150000001557 benzodiazepines Chemical class 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
229960002802 bromocriptine Drugs 0.000 description 1
229940095731 candida albicans Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
229940124558 contraceptive agent Drugs 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
210000004246 corpus luteum Anatomy 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
108091007930 cytoplasmic receptors Proteins 0.000 description 1
POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
229960000766 danazol Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000003001 depressive effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
201000003104 endogenous depression Diseases 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
235000004626 essential fatty acids Nutrition 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
229920002457 flexible plastic Polymers 0.000 description 1
235000020932 food allergy Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
235000003642 hunger Nutrition 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
206010020765 hypersomnia Diseases 0.000 description 1
230000002267 hypothalamic effect Effects 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
206010021654 increased appetite Diseases 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960004488 linolenic acid Drugs 0.000 description 1
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
229910052808 lithium carbonate Inorganic materials 0.000 description 1
229940008015 lithium carbonate Drugs 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
208000024714 major depressive disease Diseases 0.000 description 1
238000007726 management method Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
229960003464 mefenamic acid Drugs 0.000 description 1
HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
239000012528 membrane Substances 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
230000009247 menarche Effects 0.000 description 1
230000009245 menopause Effects 0.000 description 1
201000003102 mental depression Diseases 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229960001207 micronized progesterone Drugs 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
230000007510 mood change Effects 0.000 description 1
-1 naparoxen Chemical compound 0.000 description 1
230000000955 neuroendocrine Effects 0.000 description 1
235000018343 nutrient deficiency Nutrition 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
208000023112 overgrowth syndrome Diseases 0.000 description 1
230000000624 ovulatory effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
210000004560 pineal gland Anatomy 0.000 description 1
229960002702 piroxicam Drugs 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
230000006584 pituitary dysfunction Effects 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000000063 preceeding effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
229940001470 psychoactive drug Drugs 0.000 description 1
239000004089 psychotropic agent Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
201000004335 respiratory allergy Diseases 0.000 description 1
238000012552 review Methods 0.000 description 1
230000033764 rhythmic process Effects 0.000 description 1
230000035807 sensation Effects 0.000 description 1
235000019615 sensations Nutrition 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
208000018316 severe headache Diseases 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
239000011257 shell material Substances 0.000 description 1
206010040882 skin lesion Diseases 0.000 description 1
231100000444 skin lesion Toxicity 0.000 description 1
230000008454 sleep-wake cycle Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
208000021792 sore eyes Diseases 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
230000010009 steroidogenesis Effects 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
235000021147 sweet food Nutrition 0.000 description 1
230000008961 swelling Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000005495 thyroid hormone Substances 0.000 description 1
229940036555 thyroid hormone Drugs 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
231100000889 vertigo Toxicity 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000019156 vitamin B Nutrition 0.000 description 1
239000011720 vitamin B Substances 0.000 description 1
229940046001 vitamin b complex Drugs 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Reproductive Health (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Fats And Perfumes (AREA)
Diaphragms For Electromechanical Transducers (AREA)

IL9305390A 1989-01-17 1990-01-15 Pharmacological preparations and kits for the treatment of pre-menstrual syndrome IL93053A (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US07/297,328 US4945103A (en)	1989-01-17	1989-01-17	Method of treating pre-menstrual syndrome
AU51928/90A AU642864B2 (en)	1989-01-17	1990-02-09	Method of treating pre-menstrual syndrome
PCT/US1990/000154 WO1991012007A1 (en)	1989-01-17	1990-02-09	Method of treating pre-menstrual syndrome
CA002075904A CA2075904C (en)	1989-01-17	1990-02-09	Method of treating pre-menstrual syndrome

Publications (1)

Publication Number	Publication Date
IL93053A true IL93053A (en)	1994-02-27

Family

ID=27154756

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9305390A IL93053A (en)	1989-01-17	1990-01-15	Pharmacological preparations and kits for the treatment of pre-menstrual syndrome

Country Status (11)

Country	Link
US (1)	US4945103A (de)
EP (1)	EP0514373B1 (de)
KR (1)	KR0171408B1 (de)
AT (1)	ATE124260T1 (de)
AU (1)	AU642864B2 (de)
CA (1)	CA2075904C (de)
DE (1)	DE69020582T2 (de)
EG (1)	EG19304A (de)
ES (1)	ES2074565T3 (de)
IL (1)	IL93053A (de)
WO (1)	WO1991012007A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5116828A (en) *	1989-10-26	1992-05-26	Nippon Zoki Pharmaceutical Co., Ltd.	Pharmaceutical composition for treatment of osteoporosis
US6638963B1 (en)	1990-12-04	2003-10-28	Oregon Health And Science University	Methods for treating circadian rhythm disorders
US5707652A (en) *	1990-12-04	1998-01-13	State Of Oregon	Methods of treating circadian rhythm phase disorders
EP0518468B1 (de) *	1991-05-09	1999-06-30	Neurim Pharmaceuticals (1991) Limited	Melatonin enthaltende Arzneimittel
PT100973A (pt) *	1991-10-18	1994-06-30	Alza Corp	Dispositivo e composicoes farmaceuticas para a administracao de melatonina por via transdermica
ATE141051T1 (de) *	1992-04-07	1996-08-15	Neurim Pharma 1991	Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie
US5385736A (en) *	1993-07-12	1995-01-31	Minnesota Mining And Manufacturing Company	Transdermal melatonin delivery system
AU7550994A (en) *	1993-07-26	1995-02-20	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University	Sustained release oral compositions containing melatonin
US5688520A (en) *	1995-03-29	1997-11-18	Minnesota Mining And Manufacturing Company	Transmucosal delivery of melatonin for prevention of migraine
EP0901376A1 (de) *	1996-05-20	1999-03-17	Fuisz Technologies Ltd.	Melatonin in kombination mit analgetika
US5968547A (en) *	1997-02-24	1999-10-19	Euro-Celtique, S.A.	Method of providing sustained analgesia with buprenorphine
US6133453A (en) *	1998-05-15	2000-10-17	Pharm-Eco Laboratories, Inc.	Method for making substituted indoles
US20040131579A1 (en) *	1998-09-10	2004-07-08	Avon Products, Inc.	Method and compositions for reducing dermatological aging and for reducing bruising
US6479545B1 (en)	1999-09-30	2002-11-12	Drugtech Corporation	Formulation for menopausal women
DE19957710A1 (de) *	1999-11-30	2001-05-31	Asat Ag Applied Science & Tech	Verwendung von Melatonin zur Behandlung der androgenetischen Alopezie
US20020119191A1 (en) *	2000-04-24	2002-08-29	Hitoo Nishino	Pharmaceutical or food composition for treatment or prevention of brain edema
US8226972B2 (en)	2001-12-20	2012-07-24	Femmepharma Holding Company, Inc.	Vaginal delivery of drugs
MXPA05007266A (es)	2003-01-02	2006-01-17	Femmepharma Holding Co Inc	Preparaciones farmaceuticas para tratamientos de enfermedades y trastornos del seno.
US9173836B2 (en)	2003-01-02	2015-11-03	FemmeParma Holding Company, Inc.	Pharmaceutical preparations for treatments of diseases and disorders of the breast
US9358296B2 (en)	2003-02-24	2016-06-07	Pharmaceutical Productions Inc.	Transmucosal drug delivery system
US9254294B2 (en)	2003-02-24	2016-02-09	Pharmaceutical Productions Inc.	Transmucosal hormone delivery system
US9498454B2 (en)	2003-02-24	2016-11-22	Pharmaceutical Productions Inc.	Transmucosal drug delivery system
US9408405B2 (en)	2003-10-03	2016-08-09	Veijlen N.V.	Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals
CN1870992A (zh)	2003-10-03	2006-11-29	维伊林股份有限公司	动物饲料组合物
KR100776294B1 (ko) *	2006-08-30	2007-11-16	엘지전자 주식회사	냉장고
KR100835183B1 (ko) *	2006-08-30	2008-06-04	엘지전자 주식회사	냉장고
CN101516255A (zh) *	2006-09-13	2009-08-26	皇家飞利浦电子股份有限公司	用于自动调整褪黑素的剂量和/或递送褪黑素的装置
US20100119601A1 (en) *	2007-04-11	2010-05-13	Pharmaceutical Productions Inc.	Melatonin tablet and methods of preparation and use
UY33103A (es)	2009-12-15	2011-07-29	Techsphere S A De C V	Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
US9265458B2 (en)	2012-12-04	2016-02-23	Sync-Think, Inc.	Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en)	2013-03-11	2016-07-05	Sync-Think, Inc.	Optical neuroinformatics
KR102262306B1 (ko)	2013-07-04	2021-06-09	(주)아모레퍼시픽	월경 전기 증후군 및 월경통 완화의 기능을 갖는 조성물
KR102192573B1 (ko)	2020-08-12	2020-12-18	문종진	생리통 및 피부 트러블의 예방 및 개선용 조성물
CN113876689A (zh) *	2021-11-01	2022-01-04	冷静	一种改进型褪黑素的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0004770B1 (de) *	1978-04-11	1984-06-13	Efamol Limited	Pharmazeutische und diätetische Zusammensetzung mit Gehalt an Gamma-Linolensäuren
US4390531A (en) *	1981-08-10	1983-06-28	Syntex Pharmaceuticals International Ltd.	Method of contraception using peak progestogen dosage
US4600723A (en) *	1983-05-18	1986-07-15	Monash University	Method for minimizing disturbances in circadian rhythms of bodily performance and function
DE3466215D1 (en) *	1983-05-18	1987-10-22	Univ Monash	The use of melatonin for the manufacture of a medicament
US4687763A (en) *	1985-02-25	1987-08-18	Massachusetts Institute Of Technology	Composition and method for increasing levels or release of brain serotonin
US4746674A (en) *	1985-08-27	1988-05-24	Cellena (Cell Engineering) Ag	Melatonin compositions and uses thereof
US4654361A (en) *	1986-01-27	1987-03-31	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University	Method of lowering intraocular pressure using melatonin
NZ215767A (en) *	1986-04-09	1989-10-27	Nz Government	Stimulating cashmere fibre growth on cashmere-producing goats by administration of melatonin
US4855305A (en) *	1987-03-23	1989-08-08	Applied Medical Research	Compositions and methods of effecting contraception utilizing melatonin
AU1494788A (en) *	1987-04-01	1988-11-02	Cellena (Cell Engineering) A.G.	Melatonin-derivatives for psychogenic stress and acute anxiety, and immuno-stimulant drugs

1989
- 1989-01-17 US US07/297,328 patent/US4945103A/en not_active Expired - Lifetime
1990
- 1990-01-14 EG EG1690A patent/EG19304A/xx active
- 1990-01-15 IL IL9305390A patent/IL93053A/en not_active IP Right Cessation
- 1990-02-09 EP EP90904142A patent/EP0514373B1/de not_active Expired - Lifetime
- 1990-02-09 CA CA002075904A patent/CA2075904C/en not_active Expired - Fee Related
- 1990-02-09 KR KR1019910701292A patent/KR0171408B1/ko not_active Expired - Fee Related
- 1990-02-09 AT AT90904142T patent/ATE124260T1/de not_active IP Right Cessation
- 1990-02-09 WO PCT/US1990/000154 patent/WO1991012007A1/en not_active Ceased
- 1990-02-09 ES ES90904142T patent/ES2074565T3/es not_active Expired - Lifetime
- 1990-02-09 AU AU51928/90A patent/AU642864B2/en not_active Ceased
- 1990-02-09 DE DE69020582T patent/DE69020582T2/de not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ES2074565T3 (es)	1995-09-16
WO1991012007A1 (en)	1991-08-22
DE69020582D1 (de)	1995-08-03
KR920700649A (ko)	1992-08-10
EP0514373B1 (de)	1995-06-28
EG19304A (en)	1994-11-30
CA2075904A1 (en)	1991-08-10
ATE124260T1 (de)	1995-07-15
US4945103A (en)	1990-07-31
AU5192890A (en)	1991-09-03
AU642864B2 (en)	1993-11-04
EP0514373A1 (de)	1992-11-25
CA2075904C (en)	2004-07-20
DE69020582T2 (de)	1996-01-04
EP0514373A4 (en)	1993-03-17
KR0171408B1 (ko)	1999-02-01

Legal Events

Date	Code	Title
1996-06-18	KB	Patent renewed
2000-07-16	FF	Patent granted
2000-08-31	KB	Patent renewed
2004-02-19	KB	Patent renewed
2008-12-29	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
US4945103A (en)	1990-07-31	Method of treating pre-menstrual syndrome
US4855305A (en)	1989-08-08	Compositions and methods of effecting contraception utilizing melatonin
AU680239B2 (en)	1997-07-24	Hormone replacement therapy
US7078394B2 (en)	2006-07-18	Low dose estrogen interrupted hormone replacement therapy
CN1079386A (zh)	1993-12-15	口服避孕及调节月经的雌激素/孕激素/抗孕激素方法和药盒
PH26649A (en)	1992-09-04	Method of treating premenstrual syndrome
JPH08502017A (ja)	1996-03-05	月経前症候群の治療方法
EP0472628A1 (de)	1992-03-04	Verwendung von melatoninderivaten zur beeinflussung der kontrazeption
AU644367B2 (en)	1993-12-09	Use of melatonin derivatives for effecting contraception
CN1395932A (zh)	2003-02-12	雌激素/孕激素/抗孕激素的应用,其组合物和药盒
NZ244997A (en)	1996-12-20	Use of melatonin derivatives for contraception
IL94411A (en)	1996-10-16	Compositions comprising an analog of melatonin in combination with progestogen and/or estrogen for effecting contraception
IL96926A (en)	1996-01-19	Pharmaceutical compositions for alleviating post-menopausal symptoms comprising melatonin and a least one estrogen and/ or androgen